The Effects of Sorafenib on Molecular Barrett's Esophagus Cancer
To determine whether sorafenib is able to change pre-cancerous cells in a way that we believe is important in the progression of cancer.
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Pilot Study of the Effect of Sorafenib on Molecular Biomarkers in Barrett's Esophagus With High Grade Dysplasia|
- Ki-67 [ Time Frame: Two weeks ] [ Designated as safety issue: No ]Biomarker. Change in Ki-67 staining between pre- and on-therapy biopsies in patients with Barrett's esophagus.
|Study Start Date:||June 2006|
|Study Completion Date:||September 2009|
|Primary Completion Date:||September 2009 (Final data collection date for primary outcome measure)|
sorafenib 2 tablets by mouth
2 tablets with water by mouth twice a day for two weeks.
Other Name: Sorafenib
To characterize the effects of sorafenib on specific molecular markers in patients with Barrett's esophagus and high grade intraepithelial neoplasia (HGIN) or carcinoma in situ (CIS).
Please refer to this study by its ClinicalTrials.gov identifier: NCT00619242
|United States, Illinois|
|University of Chicago|
|Chicago, Illinois, United States, 60637|
|Principal Investigator:||Ezra Cohen, MD||University of Chicago|